Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer

Biochemical and Biophysical Research Communications

Volumn 463, Issue 3, 2015, Pages 161-166

  Malla, Ritu ^a   Ashby, Charles R ^b   Narayanan, Narayanan K ^c   Narayanan, Bhagavathi ^c   Faridi, Jesika S ^a   Tiwari, Amit K ^d  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TOLEDO   (United States)

Author keywords

Cancer therapeutics; mTORC1; PI3K AKT; PRAS40

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROLINE RICH AKT SUBSTRATE OF 40 KDA; PROTEIN KINASE B; UNCLASSIFIED DRUG; AKT1S1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

CANCER GROWTH; CANCER PATIENT; CARCINOGENESIS; COLON CANCER; FEEDBACK SYSTEM; HUMAN; LIVER CANCER; LUNG CANCER; MELANOMA; MICROARRAY ANALYSIS; NONHUMAN; PANCREAS CANCER; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; SIGNAL TRANSDUCTION; ANIMAL; DRUG DEVELOPMENT; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARCINOGENESIS; DRUG DISCOVERY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84930924235     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.05.041     Document Type: Short Survey

References (53)

1. M.A. Lawlor, and D.R. Alessi PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J. Cell Sci. 114 2001 2903 2910
2. J. Huang, and B.D. Manning A complex interplay between akt, TSC2 and the two mTOR complexes Biochem. Soc. Trans. 37 2009 217 222
3. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes. Dev. 18 2004 1926 1945
4. Y. Sancak, C.C. Thoreen, T.R. Peterson, R.A. Lindquist, S.A. Kang, E. Spooner, S.A. Carr, and D.M. Sabatini PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase Mol. Cell 25 2007 903 915
5. E. Vander Haar, S.I. Lee, S. Bandhakavi, T.J. Griffin, and D.H. Kim Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 Nat. Cell Biol. 9 2007 316 323
6. A.A. Kazi, and C.H. Lang PRAS40 regulates protein synthesis and cell cycle in C2C12 myoblasts Mol. Med. 16 2010 359 371
7. K.S. Kovacina, G.Y. Park, S.S. Bae, A.W. Guzzetta, E. Schaefer, M.J. Birnbaum, and R.A. Roth Identification of a proline-rich akt substrate as a 14-3-3 binding partner J. Biol. Chem. 278 2003 10189 10194
8. P. Sen, S. Mukherjee, D. Ray, and S. Raha Involvement of the Akt/PKB signaling pathway with disease processes Mol. Cell Biochem. 253 2003 241 246
9. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
10. Z.Z. Chong, Y.C. Shang, S. Wang, and K. Maiese PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection PLoS One 7 2012 e45456
11. A. Saito, P. Narasimhan, T. Hayashi, S. Okuno, M. Ferrand-Drake, and P.H. Chan Neuroprotective role of a proline-rich akt substrate in apoptotic neuronal cell death after stroke: relationships with nerve growth factor J. Neurosci. 24 2004 1584 1593
12. A. Saito, T. Hayashi, S. Okuno, T. Nishi, and P.H. Chan Modulation of proline-rich akt substrate survival signaling pathways by oxidative stress in mouse brains after transient focal cerebral ischemia Stroke 37 2006 513 517
13. Y.C. Shang, Z.Z. Chong, S. Wang, and K. Maiese Wnt1 inducible signaling pathway protein 1 (WISP1) targets PRAS40 to govern beta-amyloid apoptotic injury of microglia Curr. Neurovasc Res. 9 2012 239 249
14. M. Völkers, S. Doroudgar, N. Nguyen, M.H. Konstandin, P. Quijada, S. Din, L. Ornelas, D.J. Thuerauf, N. Gude, K. Friedrich, S. Herzig, C.C. Glembotski, and M.A. Sussman PRAS40 prevents development of diabetic cardiomyopathy and improves hepatic insulin sensitivity in obesity EMBO Mol. Med. 6 2014 57 65
15. J. Hao, F. Li, W. Liu, Q. Liu, S. Liu, H. Li, and H. Duan Phosphorylation of PRAS40-Thr246 involved in renal lipid accumulation of diabetes J. Cell Physiol. 229 2014 1069 1077
16. E.B. Nascimento, M. Fodor, G.C. van der Zon, I.M. Jazet, A.E. Meinders, P.J. Voshol, R. Vlasblom, B. Baan, J. Eckel, J.A. Maassen, M. Diamant, and D.M. Ouwens Insulin-mediated phosphorylation of the proline-rich akt substrate PRAS40 is impaired in insulin target tissues of high-fat diet-fed rats Diabetes 55 2006 3221 3228
17. C. Wiza, A. Chadt, M. Blumensatt, T. Kanzleiter, D. Herzfeld De Wiza, A. Horrighs, H. Mueller, E.B. Nascimento, A. Schurmann, H. Al-Hasani, and D.M. Ouwens Over-expression of PRAS40 enhances insulin sensitivity in skeletal muscle Arch. Physiol. Biochem. 120 2014 64 72
18. W. Kim, H. Youn, K.M. Seong, H.J. Yang, Y.J. Yun, T. Kwon, Y.H. Kim, J.Y. Lee, Y.W. Jin, and B. Youn PIM1-activated PRAS40 regulates radioresistance in non-small cell lung cancer cells through interplay with FOXO3a, 14-3-3 and protein phosphatases Radiat. Res. 176 2011 539 552
19. L. Huang, Y. Nakai, I. Kuwahara, and K. Matsumoto PRAS40 is a functionally critical target for EWS repression in ewing sarcoma Cancer Res. 72 2012 1260 1269
20. K. Yuan, H. Wu, Y. Wang, H. Chen, M. Jiao, and R. Fu Phospho-PRAS40 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer Oncol. Lett. 9 2015 785 789
21. S.G. Dann, A. Selvaraj, and G. Thomas mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer Trends Mol. Med. 13 2007 252 259
22. M. Shipitsin, C. Small, E. Giladi, S. Siddiqui, S. Choudhury, S. Hussain, Y.E. Huang, H. Chang, D.L. Rimm, D.M. Berman, T.P. Nifong, and P. Blume-Jensen Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality Proteome Sci. 12 2014 40-5956-12-40
23. Y.Z. Lu, A.M. Deng, L.H. Li, G.Y. Liu, and G.Y. Wu Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer Arch. Med. Sci. 10 2014 149 153
24. I.I. Kessler Cancer mortality among diabetics J. Natl. Cancer Inst. 44 1970 673 686
25. A. Czyżyk, and Z. Szczepanik Diabetes mellitus and cancer Eur. Journ. Int. Med. 11 5 2000 245 252
26. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat. Rev. Cancer 2 2002 489 501
27. G.P. Robertson Functional and therapeutic significance of Akt deregulation in malignant melanoma Cancer Metastasis Rev. 24 2 2005 273 285
28. J.Q. Cheng, C.W. Lindsley, G.Z. Cheng, H. Yang, and S.V. Nicosia The Akt/PKB pathway: molecular target for cancer drug discovery Oncogene 24 2005 7482 7492
29. B. Huang, and G. Porter Expression of proline-rich akt-substrate PRAS40 in cell survival pathway and carcinogenesis Acta Pharmacol. Sin. 26 2005 1253 1258
30. J.N. Andersen, S. Sathyanarayanan, A. Di Bacco, A. Chi, T. Zhang, A.H. Chen, B. Dolinski, M. Kraus, B. Roberts, W. Arthur, R.A. Klinghoffer, D. Gargano, L. Li, I. Feldman, B. Lynch, J. Rush, R.C. Hendrickson, P. Blume-Jensen, and C.P. Paweletz Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors Sci. Transl. Med. 2 2010 43ra55
31. D.R. Rhodes, S. Kalyana-Sundaram, S.A. Tomlins, V. Mahavisno, N. Kasper, R. Varambally, T.R. Barrette, D. Ghosh, S. Varambally, and A.M. Chinnaiyan Molecular concepts analysis links tumors, pathways, mechanisms, and drugs Neoplasia 9 2007 443 454
32. N.N. Baxter, M.A. Goldwasser, L.F. Paszat, R. Saskin, D.R. Urbach, and L. Rabeneck Association of colonoscopy and death from colorectal cancer Ann. Intern. Med. 150 2009 1 8
33. I. Baricevic, D.L. Roberts, and A.G. Renehan Chronic insulin exposure does not cause insulin resistance but is associated with chemo-resistance in colon cancer cells Horm. Metab. Res. 46 2014 85 93
34. X. Yu, B. Zheng, and R. Chai Lentivirus-mediated knockdown of eukaryotic translation initiation factor 3 subunit D inhibits proliferation of HCT116 colon cancer cells Biosci. Rep. 34 2014
35. P. Michielsen, and E. Ho Viral hepatitis B and hepatocellular carcinoma Acta Gastroenterol. Belg 74 2011 4 8
36. X. Ma, J. Yan, W. Chen, P. Du, J. Xie, H. Yu, and H. Wu Knockdown of myosin VI inhibits proliferation of hepatocellular carcinoma cells in vitro Chem. Biol. Drug Des. 2015 Feb 19 http://dx.doi.org/10.1111/cbdd.12544 [Epub ahead of print]
37. E.E. Vincent, D.J. Elder, E.C. Thomas, L. Phillips, C. Morgan, J. Pawade, M. Sohail, M.T. May, M.R. Hetzel, and J.M. Tavare Akt phosphorylation on Thr308 but not on Ser473 correlates with akt protein kinase activity in human non-small cell lung cancer Br. J. Cancer 104 2011 1755 1761
38. N. Khan, F. Afaq, F.H. Khusro, V. Mustafa Adhami, Y. Suh, and H. Mukhtar Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin Int. J. Cancer 130 2012 1695 1705
39. G.I. Shapiro, J. Rodon, C. Bedell, E.L. Kwak, J. Baselga, I. Brana, S.S. Pandya, C. Scheffold, A.D. Laird, L.T. Nguyen, Y. Xu, C. Egile, and G. Edelman Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors Clin. Cancer Res. 20 2014 233 245
40. F. Zhang, Z.M. Beharry, T.E. Harris, M.B. Lilly, C.D. Smith, S. Mahajan, and A.S. Kraft PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells Cancer Biol. Ther. 8 2009 846 853
41. N. Rhodes, D.A. Heerding, D.R. Duckett, D.J. Eberwein, V.B. Knick, T.J. Lansing, R.T. McConnell, T.M. Gilmer, S.Y. Zhang, K. Robell, J.A. Kahana, R.S. Geske, E.V. Kleymenova, A.E. Choudhry, Z. Lai, J.D. Leber, E.A. Minthorn, S.L. Strum, E.R. Wood, P.S. Huang, R.A. Copeland, and R. Kumar Characterization of an akt kinase inhibitor with potent pharmacodynamic and antitumor activity Cancer Res. 68 2008 2366 2374
42. S.V. Madhunapantula, A. Sharma, and G.P. Robertson PRAS40 deregulates apoptosis in malignant melanoma Cancer Res. 67 2007 3626 3636
43. A. Shimaya, K.S. Kovacina, and R.A. Roth On the mechanism for neomycin reversal of wortmannin inhibition of insulin stimulation of glucose uptake J. Biol. Chem. 279 2004 55277 55282
44. L.S. Steelman, W.H. Chappell, S.L. Abrams, R.C. Kempf, J. Long, P. Laidler, S. Mijatovic, D. Maksimovic-Ivanic, F. Stivala, M.C. Mazzarino, M. Donia, P. Fagone, G. Malaponte, F. Nicoletti, M. Libra, M. Milella, A. Tafuri, A. Bonati, J. Basecke, L. Cocco, C. Evangelisti, A.M. Martelli, G. Montalto, M. Cervello, and J.A. McCubrey Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging Aging (Albany NY) 3 2011 192 222
45. H. Pei, L. Li, B.L. Fridley, G.D. Jenkins, K.R. Kalari, W. Lingle, G. Petersen, Z. Lou, and L. Wang FKBP51 affects cancer cell response to chemotherapy by negatively regulating akt Cancer Cell 16 2009 259 266
46. B.R. Davies, H. Greenwood, P. Dudley, C. Crafter, D.H. Yu, J. Zhang, J. Li, B. Gao, Q. Ji, J. Maynard, S.A. Ricketts, D. Cross, S. Cosulich, C.C. Chresta, K. Page, J. Yates, C. Lane, R. Watson, R. Luke, D. Ogilvie, and M. Pass Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background Mol. Cancer. Ther. 11 2012 873 887
47. J. Wang, X. Xiao, Y. Zhang, D. Shi, W. Chen, L. Fu, L. Liu, F. Xie, T. Kang, W. Huang, and W. Deng Simultaneous modulation of COX-2, p300, akt, and apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells J. Pineal Res. 53 2012 77 90
48. H. Zhao, A. Langerod, Y. Ji, K.W. Nowels, J.M. Nesland, R. Tibshirani, I.K. Bukholm, R. Karesen, D. Botstein, A.L. Borresen-Dale, and S.S. Jeffrey Different gene expression patterns in invasive lobular and ductal carcinomas of the breast Mol. Biol. Cell 15 2004 2523 2536
49. C. Haqq, M. Nosrati, D. Sudilovsky, J. Crothers, D. Khodabakhsh, B.L. Pulliam, S. Federman, J.R. Miller 3rd, R.E. Allen, M.I. Singer, S.P. Leong, B.M. Ljung, R.W. Sagebiel, and M. Kashani-Sabet The gene expression signatures of melanoma progression Proc. Natl. Acad. Sci. U. S. A. 102 2005 6092 6097
50. M. Skrzypczak, K. Goryca, T. Rubel, A. Paziewska, M. Mikula, D. Jarosz, J. Pachlewski, J. Oledzki, and J. Ostrowski Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability PLoS One 5 2010
51. D.K. Vanaja, J.C. Cheville, S.J. Iturria, and C.Y. Young Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression Cancer Res. 63 2003 3877 3882
52. X. Chen, S.T. Cheung, S. So, S.T. Fan, C. Barry, J. Higgins, K.M. Lai, J. Ji, S. Dudoit, I.O. Ng, M. Van De Rijn, D. Botstein, and P.O. Brown Gene expression patterns in human liver cancers Mol. Biol. Cell 13 2002 1929 1939
53. J. Hou, J. Aerts, B. den Hamer, W. van Ijcken, M. den Bakker, P. Riegman, C. van der Leest, P. van der Spek, J.A. Foekens, H.C. Hoogsteden, F. Grosveld, and S. Philipsen Gene expression-based classification of non-small cell lung carcinomas and survival prediction PLoS One 5 2010